DNA alkylation refers to the addition of alkyl groups to specific bases, resulting in alkylation products such as O2‐alkylthymine, O4‐alkylthymine, O6‐methylguanine and O6‐ethylguanine, which cause DNA mutations.
DLK-IN-1 is a selective oral active inhibitor of bisleucine zipper kinase (DLK, MAP3K12) with Ki of 3 nM. DLK-IN-1 is active in the Alzheimer's disease model, retains excellent CNS permeability, and after multiple days of administration, its concentration